Targeted proapoptotic anticancer drug delivery system

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Developing targeted drug delivery systems (DDS) is crucial for enhancing cancer therapy efficacy and minimizing side effects.
• Conventional chemotherapy faces challenges like poor bioavailability and non-specific targeting.
• Overcoming cancer cells' intrinsic antiapoptotic defense mechanisms is a key therapeutic goal.

Purpose of the Study:

• To develop and evaluate a novel, targeted, proapoptotic anticancer drug delivery system (DDS).
• To investigate the in vitro and in vivo performance of a multi-component DDS.
• To assess the synergistic effects of combining apoptosis induction and antiapoptotic defense inhibition within a single DDS.

Main Methods:

• Conjugation of poly(ethylene glycol) (PEG) with camptothecin (CPT), LHRH peptide, and BH3 peptide to create a multicomponent DDS.
• Characterization of the DDS structure using atomic force microscopy (AFM).
• In vitro and in vivo evaluation of DDS accumulation, cellular uptake, and therapeutic efficacy in cancer models.

Main Results:

• The targeted DDS preferentially accumulated in tumor tissues.
• Active ingredients were successfully delivered into the cytoplasm and nuclei of cancer cells.
• Simultaneous apoptosis induction and inhibition of BCL2 protein significantly enhanced cytotoxicity and antitumor activity.
• The DDS with two copies of each active component per PEG molecule exhibited the highest anticancer efficiency.

Conclusions:

• The developed targeted proapoptotic DDS offers a promising strategy for cancer treatment.
• The combination of targeting, apoptosis induction, and antiapoptotic suppression leads to superior anticancer effects compared to individual components.
• The optimized DDS formulation demonstrates significant potential for clinical translation in oncology.